한글목차

세계의 바이오시뮬레이션 기술 시장은 2030년까지 85억 달러에 도달

2023년에 31억 달러로 평가된 세계의 바이오시뮬레이션 기술 시장은 분석 기간 2023년부터 2030년까지 CAGR 15.7%로 성장할 전망이며, 2030년에는 85억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 바이오시뮬레이션 소프트웨어는 CAGR 14.9%로 성장을 지속하고, 분석 기간 종료 시 57억 달러에 달할 것으로 예측됩니다. 바이오시뮬레이션 서비스 부문의 성장률은 분석 기간 동안 CAGR 17.5%로 추정됩니다.

미국 시장은 8억 1,580만 달러로 추정, 중국은 CAGR 14.5%로 성장 예측

미국의 바이오시뮬레이션 기술 시장은 2023년 8억 1,580만 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 13억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023년부터 2030년까지 CAGR은 14.5%로 전망됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 14.1%와 13.4%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 11.2%로 성장할 것으로 예측됩니다.

세계의 바이오시뮬레이션 기술 시장 동향 및 촉진요인 정리

바이오시뮬레이션 기술은 컴퓨터 지원 모델을 활용하여 생물학적 프로세스를 시뮬레이션함으로써 바이오 기술 전망에 혁명을 일으켜 의약품 개발, 질병 관리 및 새로운 치료법의 창출에 큰 영향을 미칩니다. 이 기술은 생물학적 시스템의 상세한 3차원 모델을 구축하고 복잡한 생물학적 상호작용에 대한 이해를 높이고 다양한 자극에 대한 반응을 예측하는 데 매우 중요합니다. 그 적용 범위는 의약품의 표적 검증에서 의약품 개발에서 임상시험 계획의 최적화에 이르기까지 의약품 개발의 여러 단계로 확장됩니다. 바이오시뮬레이션을 통해 제약 기업은 잠재적인 약물 실패를 조기에 발견하고, 엄청난 투자를 절약하고, 자원을 최적화함으로써 혁신을 가속화할 수 있습니다. 이 능력은 인실리코 평가에 의한 임상시험 설계의 강화에도 이르렀으며, 임상시험의 성공률을 향상시키고, 후기 임상시험의 실패라는 문제를 해결하고 있습니다.

바이오시뮬레이션 시장의 성장은 의약품 승인 프로세스를 강화하기 위해 규제기관이 바이오시뮬레이션을 채용했으며, 잠재적인 비용 절감 효과를 배경으로 제약기업과 바이오테크놀러지 기업이 연구개발 투자를 급증시키는 등 몇 가지 주요 요인에 의해 뒷받침됩니다. 또한 소프트웨어 엔지니어링의 최근 진보는 바이오시뮬레이션 모델의 신뢰성과 효율성을 향상시키는 중요한 역할을 수행합니다. 그 밖의 특전으로는 이러한 모델의 가독성, 재현성, 재이용성의 향상을 목표로 한 대처를 들 수 있고, 기술 인프라가 발달하고 있는 북미가 도입으로 리드하고 있어 다음에 생명과학 연구 증가 그리고 정부의 유리한 정책에 의해 급성장이 기대되는 아시아태평양이 계속되고 있습니다.

복잡한 데이터세트를 처리할 수 있는 컴퓨팅 능력을 향상시키고 치료의 개별화를 강화하는 개인화된 의료와 통합하는 등 여러 성장 촉진요인들이 바이오시뮬레이션 시장을 형성하고 있습니다. 학술기관과 제약기업의 공동연구를 통해 의약품 개발에 있어서의 바이오시뮬레이션 용도가 정교해지고 있습니다. 게다가 생물학적 시스템의 복잡성과 함께 첨단 모델링 툴이 요구되는 반면, 희귀질환 및 희귀질환 치료제에 대한 주목 증가, 시장 출시까지의 시간 단축에 대한 요구, 약물 재사용에 대한 노력의 강화에 의해 바이오시뮬레이션의 유용성이 부각되고 있습니다. 게다가 최근 세계의 보건보건 긴급 동향으로부터 치료제의 신속한 개발의 중요성이 부각되고 있어 바이오시뮬레이션이 중요한 역할을 하고 있습니다. 바이오시뮬레이션이 AI 및 머신러닝과 같은 기술과 융합됨으로써 그 예측 능력은 더욱 강화되고, 특히 의료 인프라가 확대되는 신흥국 시장에서는 창약 및 약제 개발에 필수적입니다.

조사 대상 기업 예(주목의 22사)

• 3DS BIOVIA
• Advanced Chemistry Development, Inc.(ACD/Labs)
• Certara USA, Inc.
• Genedata AG
• Schrodinger LLC

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향 및 촉진요인
• 세계 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 세계 기타 지역

제4장 경쟁

영문목차

Global Biosimulation Technology Market to Reach US$8.5 Billion by 2030

The global market for Biosimulation Technology estimated at US$3.1 Billion in the year 2023, is expected to reach US$8.5 Billion by 2030, growing at a CAGR of 15.7% over the analysis period 2023-2030. Biosimulation Software, one of the segments analyzed in the report, is expected to record a 14.9% CAGR and reach US$5.7 Billion by the end of the analysis period. Growth in the Biosimulation Services segment is estimated at 17.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$815.8 Million While China is Forecast to Grow at 14.5% CAGR

The Biosimulation Technology market in the U.S. is estimated at US$815.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 14.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.1% and 13.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.2% CAGR.

Global Biosimulation Technology Market - Key Trends and Drivers Summarized

Biosimulation technology is revolutionizing the biotechnology landscape by leveraging computer-assisted models to simulate biological processes, significantly impacting drug development, disease management, and the creation of new therapies. This technology is pivotal in constructing detailed three-dimensional models of biological systems, enhancing the understanding of complex biological interactions, and predicting responses to various stimuli. Its applications span multiple stages of drug development, from target validation in drug discovery to optimizing clinical trial designs in drug development. Biosimulation enables pharmaceutical companies to identify potential drug failures early, saving substantial investments and accelerating innovation by optimizing resources. This capability extends to enhancing clinical trial designs through in silico evaluations, which improve success rates and address the issue of late-stage trial failures.

The growth of the biosimulation market is propelled by several key drivers, including the adoption of biosimulation by regulatory bodies to enhance drug approval processes and a surge in R&D investments by pharmaceutical and biotechnology companies driven by potential cost savings. Recent advancements in software engineering have also played a crucial role, improving the reliability and efficiency of biosimulation models. Additionally, the market benefits from efforts aimed at enhancing the readability, reproducibility, and reuse of these models, with North America leading in adoption due to its advanced technological infrastructure, followed by the Asia Pacific region, which is expected to experience the fastest growth due to increased life sciences research and favorable government policies.

Several growth drivers are shaping the biosimulation market, such as advancements in computational power that enable handling complex data sets, and integration with personalized medicine, which enhances treatment personalization. Collaborative research efforts among academic institutions and pharmaceutical companies are refining biosimulation applications in drug development. Moreover, the growing complexity of biological systems necessitates sophisticated modeling tools, while the increased focus on rare diseases and orphan drugs, demand for faster time-to-market, and enhanced drug repurposing efforts highlight the utility of biosimulation. Additionally, the recent global health emergencies have underscored the importance of rapid development of therapeutic agents, with biosimulation playing a crucial role. The convergence of biosimulation with technologies like AI and machine learning further enhances its predictive capabilities, crucial for drug discovery and development, especially in emerging markets with expanding healthcare infrastructure.

Select Competitors (Total 22 Featured) -

• 3DS BIOVIA
• Advanced Chemistry Development, Inc. (ACD/Labs)
• Certara USA, Inc.
• Genedata AG
• Schrodinger LLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Biosimulation Technology - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Global Economic Update
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Advances in Computational Power Propel Growth of Biosimulation Technology
  • Growing Awareness of Biosimulation Benefits in Healthcare Systems Sustains Market Growth
  • Increasing Adoption of AI and Machine Learning in Biosimulation Generates Demand
  • Growing Focus on Personalized Medicine Expands Addressable Market Opportunity
  • Rising Incidence of Chronic Diseases Spurs Demand for Biosimulation Solutions
  • Innovations in Drug Development Drive Adoption of Biosimulation Platforms
  • Here's How Cloud Computing Enhances Accessibility and Scalability of Biosimulation Tools
  • Integration of Big Data Analytics in Biosimulation Throws the Spotlight on Predictive Modelling
  • Expanding Applications in Clinical Trials Sustain Growth of Biosimulation Market
  • Digital Twins in Healthcare Propel Market Expansion
  • Increasing R&D Expenditure in Pharmaceuticals Strengthens Business Case for Biosimulation
  • Growing Adoption of Biosimulation in Toxicology Studies Spurs Market Growth
  • Regulatory Pressures for Reducing Animal Testing Drives Adoption of Biosimulation
  • Advances in Genomics and Proteomics Generate New Opportunities for Biosimulation
  • Here's How Improved Accuracy and Reliability of Biosimulation Models Propel Growth
  • Demand for Cost-Effective Drug Discovery Solutions Generates Market Expansion
  • Increasing Use of Biosimulation in Biotechnology Expands Addressable Market Opportunity
  • Rising Trend of Virtual Clinical Trials Drives Adoption of Biosimulation Technology
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 2: World 7-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • TABLE 3: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 4: World 7-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World 7-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Drug Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 8: World 7-Year Perspective for Drug Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 9: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 10: World 7-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Regulatory Authorities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 14: World 7-Year Perspective for Regulatory Authorities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 15: World Recent Past, Current & Future Analysis for Academic Research Institutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 16: World 7-Year Perspective for Academic Research Institutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World 7-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 20: World 7-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 21: World Biosimulation Technology Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 22: USA Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 23: USA 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 24: USA Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 25: USA 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• CANADA
  • TABLE 28: Canada Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 29: Canada 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 30: Canada Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 31: Canada 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• JAPAN
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 34: Japan Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 35: Japan 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 36: Japan Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 37: Japan 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• CHINA
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 40: China Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 41: China 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 42: China Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 43: China 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• EUROPE
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 46: Europe Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 47: Europe 7-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • TABLE 48: Europe Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 49: Europe 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 52: Europe Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 53: Europe 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• FRANCE
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 54: France Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 55: France 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 56: France Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: France 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 58: France Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 59: France 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• GERMANY
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 60: Germany Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 61: Germany 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Germany 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 64: Germany Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 65: Germany 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• ITALY
  • TABLE 66: Italy Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 67: Italy 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Italy 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 70: Italy Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 71: Italy 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• UNITED KINGDOM
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 72: UK Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 73: UK 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 74: UK Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: UK 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 76: UK Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 77: UK 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• REST OF EUROPE
  • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 79: Rest of Europe 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Rest of Europe 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 83: Rest of Europe 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• ASIA-PACIFIC
  • Biosimulation Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 85: Asia-Pacific 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Asia-Pacific 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 89: Asia-Pacific 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030
• REST OF WORLD
  • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology by Product - Software and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 91: Rest of World 7-Year Perspective for Biosimulation Technology by Product - Percentage Breakdown of Value Sales for Software and Services for the Years 2024 & 2030
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology by Application - Drug Development, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Rest of World 7-Year Perspective for Biosimulation Technology by Application - Percentage Breakdown of Value Sales for Drug Development, Drug Discovery and Other Applications for the Years 2024 & 2030
  • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology by End-Use - Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 95: Rest of World 7-Year Perspective for Biosimulation Technology by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Contract Research Organizations, Academic Research Institutions and Regulatory Authorities for the Years 2024 & 2030

IV. COMPETITION